Why the study?
Does the BiVACOR BiVAD restore flow in an in vitro model of end-stage biventricular heart failure?
Does the BiVACOR BiVAD restore flow in an in vitro model of end-stage biventricular heart failure?
The BiVACOR rotary BiVAD successfully restored normal flow levels in an in vitro mock circulation loop, supporting its progression to in vivo animal studies.
Answers are grounded in this paper and cite their sources.
Supports preclinical advancement of the BiVACOR BiVAD; leaves open clinical translation in end-stage biventricular failure.
The BiVACOR is a novel rotary Biventricular Assist Device (BiVAD) undergoing development to treat global end-stage heart failure. The design includes left and right vanes positioned on a shared rotating hub to form a double-sided magnetically and hydrodynamically suspended centrifugal impeller. The performance of the device was assessed in a pulsatile mock circulation loop replicating end-stage biventricular heart failure, and was shown to restore flow from pathological (2 L/min) to normal levels (5 L/min). A novel technique to balance the left/right outflow of the BiVAD was also investigated, for which a maximum relative left to right outflow differential of 1.8 L/min was achieved at normal physiologic afterloads. The in vitro results encourage device progression to in vivo animal studies. Successful development of this BiVAD will provide a suitably miniature device for patients who require biventricular assistance.
No takes yet. Share an insight, caveat, or question.
Timms et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: